NCT02210871View on ClinicalTrials.gov

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 7, 2014

Primary Completion Date

June 3, 2015

Study Completion Date

June 3, 2015

Conditions
DiabetesDiabetes Mellitus, Type 2Hepatic Impaired
Interventions
DRUG

semaglutide

All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.

Trial Locations (4)

83101

Novo Nordisk Investigational Site, Bratislava

02-507

Novo Nordisk Investigational Site, Warsaw

05-200

Novo Nordisk Investigational Site, Wołomin

833 05

Novo Nordisk Investigational Site, Bratislava

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY